Since our molecular analyses indicated an activation of stemness in the SL region, we next assessed the gene expression levels of specific HCC/differentiation markers (AFP, GPC3, albumin) as well as the selected (cancer-) stemness markers (EpCAM, CD133, CK19) and pluripotency genes (NANOG). This evidence concerns the gene GPC3 and hepatocellular carcinoma.